
The U.S. Food and Drug Administration (FDA) today announced its approval for a breakthrough treatment that will bring the promise of immunotherapy and new hope to thousands of patients diagnosed with mantle cell lymphoma (MCL) whose previous treatments fail to bring them lasting remissions. There are more than 70 subtypes of lymphoma, and MCL is a particularly aggressive form of this blood cancer with a short remission from standard therapies. The median overall survival rate is betwe...